Correction: PharmacoEconomics – Open https://doi.org/10.1007/s41669-024-00490-x


In the following sentences of the first paragraph of Sect. 3, “pembrolizumab plus ipilimumab” should have been “pembrolizumab plus lenvatinib” (two instances):


“The consequences became apparent in a subsequent multiple technology appraisal (MTA; TA858, 2023), whereby neither nivolumab plus ipilimumab nor the new treatment pembrolizumab plus ipilimumab were found to be cost effective versus cabozantinib. NICE compromised, providing a positive recommendation for pembrolizumab plus ipilimumab if, and only if, nivolumab plus ipilimumab would otherwise be offered.”


The article has now been corrected so the sentences read:


“The consequences became apparent in a subsequent multiple technology appraisal (MTA; TA858, 2023), whereby neither nivolumab plus ipilimumab nor the new treatment pembrolizumab plus lenvatinib were found to be cost effective versus cabozantinib. NICE compromised, providing a positive recommendation for pembrolizumab plus lenvatinib if, and only if, nivolumab plus ipilimumab would otherwise be offered.”